Investigators at the National Cancer Institute''s Vaccine Branch have found that beta-mannosylceramide (Beta-ManCer) promotes immunity in an IFN-gamma independent mechanism and seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize beta-ManCer.
The National Cancer Institute's Surgery Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a potential cancer therapeutic based on T cells genetically engineered to express the human interleukin 12 (IL-12) cytokine only in the tumor environment.
T-cells capable of reacting to mutations in cancer patients have potential use as therapeutics. Identifying and isolating these cells from patients is a crucial step in developing these treatments. Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient’s peripheral blood lymphocytes (PBL). The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method of isolating mutation-reactive T-cells from peripheral blood.
A tumor-associated antigen Fms-Related Tyrosine Kinase 3 (FLT3 ) is known to be expressed on the cell surface of a majority of infant acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). NCI researchers have developed CARs comprising an antigen-binding fragment derived from a FLT3 targeting antibody. The resulting CARs can be used in adoptive cell therapy treatment for ALL or AML and other tumors which express FLT3. The NCI seeks licensees and/or co-development partners to commercialize this technology.
Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.
This licensing opportunity from the National Cancer Institute concerns the development of CARs comprising an antigen-binding fragment derived from the MGA271 antibody. The resulting CARs can be used in adoptive cell therapy treatment for neuroblastoma and other tumors that express CD276.
Researchers at the National Institute on Aging (NIA) have discovered novel microparticles that are formed using a coacervation process; the biodegradable microbead or microparticle is useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest. The microparticles have a matrix structure comprised of the reaction product of at least one cationic polymer, at least one anionic polymer, and a binding component (e.g. gelatin, chondroitin sulfate, avidin).
NCI researchers developed a combination therapy of histone deacetylase (HDAC) inhibitors and immunotherapies, such as checkpoint inhibitors, virus-based vaccines, monoclonal antibodies, cell-based treatments or radiopharmaceuticals. The NCI Laboratory of Tumor Immunology and Biology seeks parties to license or co-develop this method.
Researchers at the National Cancer Institute developed a novel method of immunogenic modulation in androgen and endocrine deprivation therapy. A combination of hormone therapy with immunotherapies such as PROSTVAC™, a Brachyury vaccine, PROVENGE™, ipilumimab, nivolumab, XOFIGO™, PANVAC, a yeast-MUC-1 immunotherapeutic, or HERCEPTIN™ can benefit prostate and breast cancer patients, especially those who have acquired resistances. The researchers seek parties to co-develop this method.
Investigators at the NCI discovered an Anti-TNF Induced Apoptosis (ATIA) protein, which protects cells against apoptosis. ATIA is highly expressed in glioblastoma and astrocytomas and its inhibition results in increased cell sensitivity to TNF-related apoptosis-inducing ligand induced cell death. The National Cancer Institute seeks parties interested in licensing or collaborative research to further develop, evaluate, or commercialize glioblastoma diagnostics and therapeutics.
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.
Researchers at the National Cancer Institute (NCI) seek research collaborations or licensees for a monoclonal antibody targeting CD276, also known as B7-H3, and related conjugates. The antibody and antibody drug conjugates (ADC) containing the antibody of the current invention were tested in vivo and have potential for use in cancer immunotherapy.